| Autor: |
Demirkan, Fatma G��l, Ulu, Kadir, ��zt��rk, K��bra, Karada��, ��erife G��l, ��zdel, Semanur, S��nmez, Hafize Emine, ��akmak, Figen, Demir, Ferhat, S��zeri, Bet��l, Ayaz, Nuray Aktay |
| Rok vydání: |
2021 |
| Předmět: |
|
| DOI: |
10.6084/m9.figshare.17031748 |
| Popis: |
To review the real-life data, to provide an input to the literature concerning treatment of juvenile idiopathic arthritis (JIA) with adalimumab (ADL) biosimilar. This multi-centric retrospective study was conducted among children with JIA, followed up for at least 24-weeks from the initiation of ADL biosimilar (ABP 501) treatment. Adverse events and alterations in disease activity scores were figured out. The median age of the group was 15.5 (5���18) years. JIA categories were oligoarticular (n =12), enthesitis-related (ERA) (n=24), psoriatic (PsA) (n=6), and polyarticular (n=4). Uveitis was detected at the initiation of the disease (n=3), during the disease course (n=5), or before the diagnosis (n=1). The first-line treatment preferences were ADL biosimilar (n=37) and etanercept (n=9). On the 6th month of ABP 501, 40 (86.9%) patients had achieved complete remission. Six patients (1 PsA, 1 polyarticular JIA, and 4 ERA) had ongoing active arthritis. Furthermore, all except one of the patients had remission of ophthalmologic findings. No life-threatening adverse events were observed. ABP 501 has a gradual increase in prescription in pediatric rheumatology. Real-life data of the cohort announce that ADL biosimilar is a suitable and effective treatment option for patients with JIA in case of indication. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
